FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) in Pediatric Patients with Serious Gram-Negative Infections

July 19, 2026

Shionogi Japan

Overview

The FDA has accepted Shionogi’s supplemental New Drug Application (sNDA) for Fetroja® (cefiderocol) to treat serious infections caused by susceptible Gram-negative bacteria in pediatric patients. This submission addresses a critical therapeutic gap for young patients facing drug-resistant pathogens. The application is supported by comprehensive safety, tolerability, and pharmacokinetic studies, highlighting a significant step towards expanding treatment options for a vulnerable population.

In Depth

Key Findings

Shionogi & Co., Ltd., has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Fetroja® (cefiderocol), a siderophore cephalosporin antibiotic. This sNDA seeks to expand the indication of Fetroja® for use in pediatric patients suffering from serious infections caused by susceptible Gram-negative bacteria. The acceptance by the FDA marks a crucial step in addressing a significant therapeutic gap for young patients confronting drug-resistant pathogens.

Technical / Clinical Details

Fetroja® (cefiderocol) employs a unique mechanism of action, utilizing a siderophore to actively transport into bacterial cells by mimicking iron uptake. This allows it to penetrate the outer membrane of Gram-negative bacteria, including highly resistant strains such as carbapenem-resistant pathogens, and exert potent antibacterial activity. The sNDA submission is supported by extensive clinical data from studies conducted in pediatric populations, evaluating the safety, tolerability, and pharmacokinetics of Fetroja® in children. These studies aimed to establish appropriate dosing regimens for various pediatric age groups and confirm that the efficacy profile observed in adults is maintained in younger patients. While specific patient numbers were not disclosed, the data package is robust enough to warrant FDA review, underscoring the high unmet medical need in pediatric serious Gram-negative infections.

Background & Context

Serious infections caused by Gram-negative bacteria, particularly multidrug-resistant strains, represent a global public health crisis. Pediatric patients are especially vulnerable to these challenging infections, yet the development of safe and effective antibiotics specifically for children has historically lagged due to complex ethical and regulatory considerations. Fetroja® is already approved for specific serious infections in adults, serving as a critical last-line treatment option when other antibiotics fail due. The proposed expansion into the pediatric population significantly enhances the clinical utility of Fetroja®, addressing a profound unmet medical need for a fragile patient group.

Strategic Significance & Outlook

The FDA’s acceptance of the sNDA for Fetroja® is a major advancement towards its potential approval for pediatric use. This could lead to a priority review or expedited pathway by the FDA. If approved, it would provide pediatricians with a powerful and reliable therapeutic option for treating life-threatening Gram-negative infections in children, significantly strengthening the arsenal against antimicrobial resistance in pediatric infectious diseases. For Shionogi, this expansion not only broadens Fetroja®’s market reach but also reinforces the company’s leadership in the infectious disease space. This development will be seen as a significant contribution to the global effort to combat antimicrobial resistance, benefiting both patients and public health systems worldwide.

Source: https://www.shionogi.com/global/en/news/2026/07/20260717.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.